Unum drops another program for troubled PhI therapy, moving its eggs to the solid tumor basket
Several months after Unum Therapeutics ran into a second safety crisis surrounding its premier Phase I therapy, the biotech is putting another ACTR087 trial to bed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.